Related Experiment Video

Updated: Jul 11, 2026

Quantification of Hypopigmentation Activity In Vitro
06:08

Quantification of Hypopigmentation Activity In Vitro

Published on: March 6, 2019

N-trans-feruloyltyramine as a melanin biosynthesis inhibitor

Mai Efdi1, Kenji Ohguchi, Yukihiro Akao

  • 1Department of Chemistry, Faculty of Engineering, Gifu University, Japan.

Biological & Pharmaceutical Bulletin
|October 6, 2007
PubMed

Insights

N-trans-feruloyltyramine (FA) effectively inhibits melanogenesis and melanin biosynthesis in melanoma cells. This compound shows greater potency than kojic acid by reducing tyrosinase expression.

Area of Science:

  • Biochemistry
  • Dermatology
  • Cell Biology

Background:

  • Melanogenesis is a complex biological process responsible for skin pigmentation.
  • Dysregulation of melanogenesis is implicated in various skin conditions and cancers.
  • Identifying novel inhibitors of melanogenesis is crucial for therapeutic applications.

Purpose of the Study:

  • To investigate the inhibitory effects of N-trans-feruloyltyramine (FA) on melanogenesis.
  • To compare the efficacy of FA with a known melanogenesis inhibitor, kojic acid.
  • To elucidate the molecular mechanisms underlying FA's action on melanin production.

Main Methods:

  • Utilized mouse B16 melanoma cell line as a model system.
  • Administered varying concentrations of FA to assess dose-dependent effects.
  • Quantified melanin content and tyrosinase expression levels.

Main Results:

  • N-trans-feruloyltyramine (FA) significantly inhibited melanogenesis in a dose-dependent manner.
  • FA demonstrated superior inhibitory potency compared to kojic acid.
  • FA treatment led to a marked decrease in tyrosinase expression levels.
  • Downregulation of tyrosinase by FA resulted in suppressed melanin biosynthesis.

Conclusions:

  • N-trans-feruloyltyramine (FA) is a potent inhibitor of melanogenesis in mouse melanoma cells.
  • FA acts by downregulating tyrosinase expression, thereby suppressing melanin production.
  • FA represents a promising agent for potential therapeutic interventions targeting hyperpigmentation disorders.

More Related Videos

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...